Post-earnings recap
Reported
Thu, Mar 14, 2024
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Enliven Therapeutics reported a narrower loss per share than expected, which is a positive sign for the company. However, the stock fell by nearly 6% following the earnings report, indicating that investors may have been looking for more clarity or additional positive news. The lack of revenue data and guidance may have contributed to the negative stock reaction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.47 | N/A | +16.07% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based solely on numerical results.